An experimental GlaxoSmithKline drug, designed to fight heart disease in a new way, failed to meet its main goal in a major late-stage clinical study, dealing a blow to one of the company’s biggest new treatment hopes.
Darapladib’s inability to reduce the risk of heart attacks and strokes in the first of two big Phase III clinical studies is disappointing, but not a huge surprise. Many analysts already had low expectations for the project.
The once-daily pill did produce greater reductions in serious coronary events in some of the pre-defined secondary endpoints of the trial, which GSK said required more analysis.
Darapladib is designed to prevent heart attacks and strokes in a completely different way from cholesterol-lowering drugs by targeting an enzyme called Lp-PLA2 that is linked to artery-clogging plaques.
While some industry analysts have suggested it could become a US$10 billion-a-year seller, if it works, few have penciled in significant sales forecasts so far, given uncertainty about the product.
Current consensus forecasts point to annual sales of only US$605 million in 2018, according to Thomson Reuters Pharma.
Patrick Vallance, GSK’s head of pharmaceuticals R&D, said Britain’s biggest drugmaker would continue to investigate the role of Lp-PLA2 inhibition in coronary heart disease and other conditions, while also poring over the latest trial results.
“We will now work to better understand the data, including evaluation of the patient sub-groups, and await the outcome of a second Phase III study of darapladib in acute coronary syndrome,” he said.
The first trial, known as STABILITY, enrolled nearly 16,000 patients with coronary heart disease in 39 countries and measured the differences in outcomes between giving them darapladib or a placebo pill.
A second 13,000-patient study, called SOLID-TIMI 52, is due to complete in March next year and is looking at patients who have already suffered an acute coronary event. It will assess if darapladib can prevent a secondary attack.
Some medical experts believe darapladib may have a better chance of success in the second study.
DAMAGE REPORT: Global central banks are assessing war-driven inflation risks as the law of unintended consequences careens around the world, spiking oil prices Central banks from Washington to London and from Jakarta to Taipei are about to make their first assessments of economic damage after more than two weeks of conflict between the US and Iran. Decisions this week encompassing every member of the G7 and eight of the world’s 10 most-traded currency jurisdictions are likely to confirm to investors that the specter of a new inflation shock is already worrying enough to prompt heightened caution. The US Federal Reserve is widely expected to do exactly what everyone anticipated weeks ahead of its March 17-18 policy gathering: hold rates steady. The narrative surrounding that
Apple Inc increased iPhone production in India by about 53 percent last year and now makes a quarter of its marquee devices there, reflecting the US company’s efforts to avoid tariffs on China. The company assembled about 55 million iPhones in India last year, up from 36 million a year earlier, people familiar with the matter said, asking not to be named because the numbers aren’t public. Apple makes about 220 million to 230 million iPhones a year globally, with India’s share of the total increasing rapidly. Apple has accelerated its expansion in the world’s most populous country in recent years, bolstered
Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) share of the global foundry market rose to almost 70 percent last year amid booming demand for artificial intelligence (AI), market information advisory firm TrendForce Corp (集邦科技) said on Thursday. The contract chipmaker posted US$122.54 billion in revenue, up 36.1 percent from a year earlier, accounting for 69.9 percent of the global market, TrendForce said. Its share was up from 64.4 percent in 2024, it said. TSMC’s closest rival, Samsung Electronics, was a distant second, posting US$12.63 billion in sales, down 3.9 percent from a year earlier, for a 7.2 percent share of the global market. In the
HEADWINDS: The company said it expects its computer business, as well as consumer electronics and communications segments to see revenue declines due to seasonality Pegatron Corp (和碩) yesterday said it aims to grow its artificial intelligence (AI) server revenue more than 10-fold this year from last year, driven by orders from neocloud solutions clients and large cloud service providers. The electronics manufacturing service provider said AI server revenue growth would be driven primarily by the Nvidia Corp GB300 server platform. Server shipments are expected to increase each quarter this year, with the second half likely to outperform the first half, it said. The AI server market is expected to broaden this year as more inference applications emerge, which would drive demand for system-on-chip, application-specific integrated circuits
RSS